ABCL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ABCL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. AbCellera Biologics's Average Total Inventories for the quarter that ended in Mar. 2024 was $0.92 Mil. AbCellera Biologics's Revenue for the three months ended in Mar. 2024 was $9.95 Mil. AbCellera Biologics's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 0.09.
AbCellera Biologics's Inventory-to-Revenue for the quarter that ended in Mar. 2024 declined from Dec. 2023 (0.13) to Dec. 2023 (0.09)
A decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenueDays Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inventory Turnover measures how fast the company turns over its inventory within a year. AbCellera Biologics's Inventory Turnover for the quarter that ended in Mar. 2024 was 0.00.
The historical data trend for AbCellera Biologics's Inventory-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AbCellera Biologics Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Inventory-to-Revenue | Get a 7-Day Free Trial | 0.01 | - | - | - | 0.04 |
AbCellera Biologics Quarterly Data | ||||||||||||||||||||
Dec18 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Inventory-to-Revenue | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
0.12 | 0.14 | 0.20 | 0.13 | 0.09 |
For the Biotechnology subindustry, AbCellera Biologics's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, AbCellera Biologics's Inventory-to-Revenue distribution charts can be found below:
* The bar in red indicates where AbCellera Biologics's Inventory-to-Revenue falls into.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
AbCellera Biologics's Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as
Inventory-to-Revenue (A: Dec. 2023 ) | |||||||
= | Average Total Inventories | / | Revenue | ||||
= | ( (Total Inventories (A: Dec. 2022 ) | + | Total Inventories (A: Dec. 2023 )) | / | count ) | / | Revenue (A: Dec. 2023 ) |
= | ( (1.532 | + | 1.107) | / | 2 ) | / | 38.025 |
= | 1.3195 | / | 38.025 | ||||
= | 0.03 |
AbCellera Biologics's Inventory-to-Revenue for the quarter that ended in Mar. 2024 is calculated as
Inventory-to-Revenue (Q: Mar. 2024 ) | |||||||
= | Average Total Inventories | / | Revenue | ||||
= | ( (Total Inventories (Q: Dec. 2023 ) | + | Total Inventories (Q: Mar. 2024 )) | / | count ) | / | Revenue (Q: Mar. 2024 ) |
= | ( (1.107 | + | 0.738) | / | 2 ) | / | 9.954 |
= | 0.9225 | / | 9.954 | ||||
= | 0.09 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AbCellera Biologics (NAS:ABCL) Inventory-to-Revenue Explanation
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenueLikewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenueMore Related Terms:
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
AbCellera Biologics's Days Inventory for the three months ended in Mar. 2024 is calculated as:
Days Inventory | = | Average Total Inventories (Q: Mar. 2024 ) | / | Cost of Goods Sold (Q: Mar. 2024 ) | * | Days in Period |
= | 0.9225 | / | 0 | * | 365 / 4 | |
= |
2. Inventory Turnover measures how fast the company turns over its inventory within a year.
AbCellera Biologics's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as
Inventory Turnover | = | Cost of Goods Sold (Q: Mar. 2024 ) | / | Average Total Inventories (Q: Mar. 2024 ) |
= | 0 | / | 0.9225 | |
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of AbCellera Biologics's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
John S. Montalbano | director | C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1 |
Michael R Hayden | director | C/O ASPREVA PHARMACEUTICALS CORPORATION, 1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8 |
Veronique Lecault | director, officer: Chief Operating Officer | C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1 |
Thermopylae Holdings Ltd. | 10 percent owner | 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1 |
Andrew Booth | officer: Chief Financial Officer | C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1 |
Andrew Lo | director | C/O ALPHASIMPLEX GROUP, LLC, ONE CAMBRIDGE CENTER, 9TH FLOOR, CAMBRIDGE MA 02142 |
John Hamer | director, 10 percent owner | PO BOX 14528, RESEARCH TRIANGLE PARK NC 27709-4528 |
Ester Falconer | officer: Chief Technology Officer | C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1 |
Hansen Carl L. G. | director, 10 percent owner, officer: Chief Executive Officer | C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1 |
Tryn Stimart | officer: Chief Legal Officer | C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1 |
Peter Thiel | director | 9200 SUNSET BOULEVARD, SUITE 1110, WEST HOLLYWOOD CA 90069 |
Dcvc Bio, L.p. | 10 percent owner | 317 UNIVERSITY AVENUE, SUITE 200, PALO ALTO CA 94301 |
Dcvc Bio Gp, Llc | 10 percent owner | 270 UNIVERSITY AVENUE, PALO ALTO CA 94301 |
Zachary Bogue | 10 percent owner | 270 UNIVERSITY AVENUE, PALO ALTO CA 94301 |
Matthew Ocko | 10 percent owner | 270 UNIVERSITY AVENUE, PALO ALTO CA 94301 |
From GuruFocus
By Business Wire • 10-31-2023
By Business Wire Business Wire • 01-24-2023
By Business Wire • 08-03-2023
By Business Wire Business Wire • 01-04-2023
By Business Wire • 07-06-2023
By Business Wire • 11-03-2023
By Business Wire Business Wire • 05-24-2023
By Business Wire Business Wire • 05-29-2023
By Business Wire Business Wire • 11-10-2022
By Business Wire Business Wire • 12-15-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.